uniQure (QURE) Interest Expenses (2016 - 2026)
uniQure (QURE) posted quarterly Interest Expenses of $14.4 million for Q2 2026, down 7.86% year-over-year from $15.6 million in Q2 2025, and up 2.39% quarter-over-quarter from $14.0 million in Q1 2026.
Analysis
uniQure (QURE) Interest Expenses (2016 - 2026) Analysis & Trends
uniQure's Interest Expenses history runs 12 years deep, the most recent figure standing at $14.4 million for Q2 2026.
- In Q2 2026, Interest Expenses fell 7.86% year-over-year to $14.4 million; the TTM figure through Jun 2026 stood at $22.8 million (down 69.92% YoY), while the FY2025 annual figure was $271.4 million, up 41.47% from the prior year.
- Interest Expenses for Q2 2026 stood at $14.4 million, up from $14.0 million in the prior quarter.
- The five-year high for Interest Expenses was $30.7 million in Q4 2023, with the low at -$22.4 million in Q4 2025.
- The 5-year median for Interest Expenses is $14.7 million (2025), against an average of $10.9 million.
- The sharpest annual moves came in 2023 and 2025: Interest Expenses soared 3067.05% in 2023, then tumbled 178.79% in 2025.
- uniQure's Interest Expenses stood at $968000.0 in 2022, then jumped by 3067.05% to $30.7 million in 2023, then slipped by 7.46% to $28.4 million in 2024, then plunged by 178.79% to -$22.4 million in 2025, then soared by 164.27% to $14.4 million in 2026.
- Business Quant data shows QURE's Interest Expenses at $14.4 million in Q2 2026, $14.0 million in Q1 2026, and -$22.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -1.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 23.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 39.74 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 93.62 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 20.27 Mn |
| 10 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 14.37 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.37 Mn |
| Mar 31, 2026 | 14.03 Mn |
| Dec 31, 2025 | 14.57 Mn |
| Sep 30, 2025 | 16.72 Mn |
| Jun 30, 2025 | 15.59 Mn |
| Mar 31, 2025 | 15.11 Mn |
| Dec 31, 2024 | 14.88 Mn |
| Sep 30, 2024 | 16.61 Mn |
| Jun 30, 2024 | 16.16 Mn |
| Mar 31, 2024 | 16.10 Mn |
| Dec 31, 2023 | 15.71 Mn |
| Sep 30, 2023 | 15.44 Mn |
| Jun 30, 2023 | 6.84 Mn |
| Mar 31, 2023 | 3.56 Mn |
| Dec 31, 2022 | 3.43 Mn |
| Sep 30, 2022 | 3.07 Mn |
| Jun 30, 2022 | 2.69 Mn |
| Mar 31, 2022 | 2.52 Mn |
| Dec 31, 2021 | 2.10 Mn |
| Sep 30, 2021 | 1.92 Mn |